Amylyx Pharmaceuticals (AMLX) Income from Continuing Operations (2021 - 2026)

Amylyx Pharmaceuticals' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 41209000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 14.77% year-over-year to 41209000.0; the TTM figure through Mar 2026 stood at 5460000.0 (up 97.5% YoY), while the FY2025 annual figure was 158000.0, up 99.95% from the prior year.
• Income from Continuing Operations was 41209000.0 for Q1 2026 at Amylyx Pharmaceuticals, down from 111578000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 111578000.0 in Q4 2025 to a low of 118793000.0 in Q1 2024.
• Historically, Income from Continuing Operations has averaged 29039470.59 across 5 years, with a median of 41209000.0 in 2026.
• The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations plunged 7652.0% in 2024, then soared 402.03% in 2025.
• A 5-year view of Income from Continuing Operations shows it stood at 42704000.0 in 2022, then surged by 106.32% to 2697000.0 in 2023, then sank by 1469.78% to 36943000.0 in 2024, then jumped by 402.03% to 111578000.0 in 2025, then sank by 136.93% to 41209000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 41209000.0 (Q1 2026), 111578000.0 (Q4 2025), and 34386000.0 (Q3 2025), per Business Quant data.